Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ikena Oncology (IKNA)
NASDAQ:IKNA
Holding IKNA?
Track your performance easily
IKNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.22 - $2.30
Previous Close$1.67
Volume582.61K
Average Volume (3M)153.67K
Market Cap
$80.59M
Enterprise Value-$49.05M
Total Cash (Recent Filing)$138.03M
Total Debt (Recent Filing)$8.39M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Mar 18, 2025EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding48,258,111
10 Day Avg. Volume118,354
30 Day Avg. Volume153,670
Standard Deviation0.24
R-Squared0.00932
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.60
Price to Sales (P/S)113.51
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-74.54
Enterprise Value/Gross Profit-5.35
Enterprise Value/Ebitda0.81
Forecast
1Y Price Target
$4.00Price Target Upside161.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Ikena Oncology News
PremiumCompany Announcements
Ikena Oncology and Inmagene Announce Merger and Fundraising
PremiumCompany Announcements
Ikena Oncology Reports Strategic Realignment and Financial Performance
PremiumCompany Announcements
Ikena Oncology Promotes Jotin Marango to Chief Operating OfficerRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IKNA FAQ
What was Ikena Oncology’s price range in the past 12 months?
Ikena Oncology lowest stock price was $1.22 and its highest was $2.30 in the past 12 months.
What is Ikena Oncology’s market cap?
Currently, no data Available
When is Ikena Oncology’s upcoming earnings report date?
Ikena Oncology’s upcoming earnings report date is Mar 18, 2025 which is in 83 days.
How were Ikena Oncology’s earnings last quarter?
Ikena Oncology released its earnings results on Nov 07, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.255 by $0.045.
Is Ikena Oncology overvalued?
According to Wall Street analysts Ikena Oncology’s price is currently Undervalued.
Does Ikena Oncology pay dividends?
Ikena Oncology does not currently pay dividends.
What is Ikena Oncology’s EPS estimate?
Ikena Oncology’s EPS estimate is -$0.27.
How many shares outstanding does Ikena Oncology have?
Ikena Oncology has 48,258,110 shares outstanding.
What happened to Ikena Oncology’s price movement after its last earnings report?
Ikena Oncology reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.255. Following the earnings report the stock price went down -1.744%.
Which hedge fund is a major shareholder of Ikena Oncology?
Among the largest hedge funds holding Ikena Oncology’s share is Omega Fund Management, LLC. It holds Ikena Oncology’s shares valued at 4M.
---
Ikena Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (161.44% Upside)
$4.00 (161.44% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.10%
12-Months-Change
Fundamentals
Return on Equity
-37.08%
Trailing 12-Months
Asset Growth
-30.81%
Trailing 12-Months
Company Description
Ikena Oncology
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
---
IKNA Stock 12 Month Forecast
Average Price Target
$4.00
▲(161.44% Upside)
Technical Analysis
Best Analysts Covering IKNA
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-15.16%
reiterated a buy rating last month
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -15.16% per trade.
---